Skip to main content

Table 2 Diagnostic performance of CE US LI-RADS and ultrasomics

From: Differentiation between combined hepatocellular cholangiocarcinoma and hepatocellular carcinoma: comparison of diagnostic performance between ultrasomics-based model and CEUS LI-RADS v2017

 

Entire cohort

Validation cohort

P

LI-RADS

Ultrasomics

LI-RADS

Ultrasomics

Sensitivity

67.0 (57.2−75.8)

97.2 (92.0−99.4)

81.3 (63.6−92.8)

90.6 (75.0−98.0)

0.476

Specificity

73.6 (59.7−84.7)

96.2 (87.0−99.5)

87.5 (61.7−98.4)

87.5 (61.7−98.4)

1.000

PPV

83.5 (76.0−89.0)

98.1 (93.3−99.8)

92.9 (77.9−98.0)

93.5 (78.6−99.2)

1.000

NPV

52.7 (44.8−60.4)

94.4 (84.6−98.8)

70.0 (52.6−83.1)

82.4 (56.6−96.2)

0.257

Accuracy

69.2% (61.4−76.3)

96.2% (93.3−99.2)

83.3% (69.8−92.5)

90.0% (80.9−98.2)

0.552

AUC*

0.703 (0.625−0.773)

0.981 (0.946−0.996)

0.844 (0.710−0.932)

0.895 (0.772−0.965)

0.501

  1. Data are percentages, with 95% confidence interval in parentheses
  2. aData are area under the ROC curve, with 95% confidence interval in parentheses